While Toll-like receptors 7 and 8 (TLR7/8) are critical for initiating immune responses against pathogens, how they avoid activation by the abundance of host RNAs generated during routine apoptotic clearance has long remained an enigma. We recently solved this mystery by demonstrating that TLR7/8 are naturally antagonized by endogenous ribosomal RNA fragments containing 2'-O-methyl (2'-OMe) guanosine (Alharbi et al., Nature Immunology 2026). Structural determination of TLR7 complexed with these natural antagonists revealed F507 as the key gatekeeper residue governing this interaction, a finding underscored by our discovery that F507 mutation drives systemic lupus in human patients. Building on this natural immune checkpoint, we developed a 3-base therapeutic oligonucleotide that potently antagonises TLR7 and TLR8, that successfully blunts inflammation in preclinical skin lupus models (Sapkota et al., bioRxiv 2026), and has recently completed a Phase 1 clinical trial for topical skin lupus management. Together, our work redefines the paradigm of self-RNA recognition and provides a direct, structurally-guided therapeutic framework for the clinical translation of novel autoimmune therapeutics.